Recent research suggests that starting statin therapy soon after being diagnosed with type 2 diabetes might not only benefit heart health but could also reduce the risk of developing dementia. A significant study presented at the European Society of Cardiology Congress found that individuals who initiated statin use within a year of their diabetes diagnosis had a 15% lower relative risk of dementia over the following decade, compared to those who delayed treatment for at least five years.
Even for those who started statins after one to five years, there was still a noticeable 10% reduction in relative risk, as detailed in findings published in The Lancet Regional Health – Europe. Statins are medications that lower “bad” LDL cholesterol levels, which helps to minimize the chances of heart attacks and strokes.
The researchers analyzed health data from over 132,000 Danish patients diagnosed with type 2 diabetes between 2006 and 2019, all of whom had no previous history of using statins or being diagnosed with dementia.
During an average follow-up period of 7.1 years, the study examined how the timing of statin treatment affected overall dementia rates. Dr. Liron Sinvani, a geriatrician, highlighted that this study is notably well-structured and adds to mounting evidence suggesting that statins could play a protective role in brain health.
While a 15% reduction may seem modest, Dr. Sinvani emphasized its significance. People with type 2 diabetes often face increased risks of cognitive decline as well as heart disease, which aligns with previous research findings.
Although there are guidelines recommending statin use for many adults aged 40 to 75 with diabetes, treatment initiation is not always prompt following a diagnosis. The study explored the connection between the timing of statin therapy and dementia risk, revealing that premature treatment correlates with decreased risk.
Dr. Sinvani pointed out that the findings encourage earlier discussions about statin therapy as part of routine diabetes care. The results seemed particularly compelling since the decrease in dementia risk was mainly related to vascular dementia rather than Alzheimer’s disease. She also noted that the biological rationale makes sense—statins are known to lower cholesterol, decrease inflammation, and protect blood vessels, all of which likely contribute to reducing vascular damage in the brain.
In light of this, statin therapy should be considered as part of a holistic approach to health that includes regular exercise, a balanced diet, and social engagement, according to experts.
Nonetheless, it’s important to recognize that the study is observational, meaning it indicates a strong correlation but doesn’t establish a direct causal relationship between statin use and dementia prevention. As Dr. Sinvani cautioned, while the findings are promising, they do not conclusively prove that statins prevent dementia. She believes, however, that this research is a crucial step forward in understanding the issue.
For those with type 2 diabetes who aren’t on statins, it’s advisable to consult with a healthcare provider about whether this treatment may be suitable for them.
